In an older adult with a catheter‑associated urinary tract infection caused by methicillin‑resistant Staphylococcus aureus (MRSA), is it appropriate to treat with nitrofurantoin (Macrobid) and levofloxacin together?

Nitrofurantoin (Macrobid) and Levofloxacin Are Not Appropriate for Catheter-Associated MRSA UTI

No, this combination is inappropriate because nitrofurantoin is FDA-approved only for acute uncomplicated cystitis and explicitly lacks the tissue distribution required for complicated infections, while levofloxacin has no activity against MRSA. 12

Why This Regimen Fails

Nitrofurantoin (Macrobid) Is Contraindicated

• The FDA label explicitly states that Macrobid is indicated only for acute uncomplicated UTI (acute cystitis) caused by susceptible E. coli or Staphylococcus saprophyticus—not for complicated infections, pyelonephritis, or perinephric abscesses. 1

• Nitrofurantoin "lacks the broader tissue distribution of other therapeutic agents approved for urinary tract infections," making it unsuitable for catheter-associated infections where biofilm formation and tissue invasion occur. 1

• The FDA warns that "many patients treated with Macrobid are predisposed to persistence or reappearance of bacteriuria" and recommends selecting agents with broader tissue distribution when bacteriuria persists. 1

• All UTIs in catheterized patients are classified as complicated by definition, placing them outside nitrofurantoin's approved indication. 3

Levofloxacin Has No MRSA Activity

• Fluoroquinolones including levofloxacin have no reliable activity against methicillin-resistant Staphylococcus aureus (MRSA), rendering levofloxacin ineffective as monotherapy for this pathogen. 2

• Even if the isolate were methicillin-susceptible S. aureus, the European Association of Urology recommends fluoroquinolones only when local E. coli resistance is <10%, and this guidance does not extend to staphylococcal infections. 3

Correct Management of Catheter-Associated MRSA UTI

First-Line Antibiotic Selection

• For MRSA catheter-associated UTI, vancomycin is the standard first-line agent (typically 15–20 mg/kg IV every 8–12 hours, adjusted for renal function and trough levels). 4

• Alternative agents with MRSA activity and urinary penetration include:

  • Linezolid 600 mg IV or PO every 12 hours (excellent oral bioavailability allows early transition) 4
  • Daptomycin 6–8 mg/kg IV once daily (higher doses may be needed for complicated infections) 4
  • Trimethoprim-sulfamethoxazole (if susceptible on culture) 1–2 double-strength tablets PO twice daily or equivalent IV dosing 3

Treatment Duration

• Standard duration is 7 days for complicated UTI once the catheter has been removed or replaced. 3

• If the catheter must remain in place or prostatitis cannot be excluded in a male patient, extend therapy to 14 days. 3

Mandatory Catheter Management

• Remove or replace the indwelling catheter as soon as clinically feasible, because biofilm on the catheter surface protects organisms from both antimicrobials and host immunity. 56

• If the catheter cannot be removed, replace it at the start of antimicrobial therapy to reduce biofilm burden and improve treatment response. 5

• Obtain urine culture and susceptibility testing immediately before starting antibiotics to enable targeted therapy once results are available. 3

Diagnostic Confirmation

• Ensure the patient has clinical symptoms (fever, flank pain, suprapubic tenderness, altered mental status, or hemodynamic instability) in addition to a positive culture, because asymptomatic bacteriuria is extremely common in catheterized patients and should not be treated. 37

• A negative urine dipstick for both nitrite and leukocyte esterase has excellent negative predictive value and can help rule out UTI in elderly or catheterized patients with nonspecific symptoms. 3

Common Pitfalls to Avoid

• Do not treat asymptomatic bacteriuria in catheterized patients, even when MRSA is isolated; this leads to unnecessary antibiotic exposure and promotes resistance without clinical benefit. 37

• Do not use nitrofurantoin for any catheter-associated infection, regardless of the pathogen, because its poor tissue distribution and high rates of bacteriuria persistence make it ineffective. 1

• Do not assume fluoroquinolones cover Gram-positive cocci; levofloxacin and ciprofloxacin have minimal to no activity against MRSA and unreliable activity against enterococci. 32

• Catheterized patients, especially nursing home residents, have significantly higher rates of multidrug-resistant organisms (including MRSA and 3MRGN Gram-negatives), requiring culture-directed therapy rather than empirical regimens designed for uncomplicated UTI. 84